LaserBlood Project

Advanced blood-based testing for detection of circulating tumor DNA and other biomarkers. Provides non-invasive alternatives to tissue biopsy for cancer diagnosis and monitoring.

A targeted blood-based early detection service for specific cancer types utilizing gene methylation biomarkers. This clinical testing service is performed by BioChain's certified medical laboratory.

First nanomechanical biomarker platform for cancer diagnosis and treatment optimization, enabling physicians to personalize therapeutic strategies.

Precision diagnostic service utilizing liquid biopsy technology for early detection and monitoring of malignant tumors. Analyzes circulating biomarkers from patient blood samples. Enables non-invasive assessment of tumor characteristics and treatment response.

Multi-biomarker screening solution for early-stage cancer identification. Analyzes blood samples to detect cancer-associated molecular signatures. Facilitates timely clinical intervention and improved patient outcomes.

Advanced liquid biopsy system for non-invasive detection and analysis of circulating tumor markers, circulating tumor cells, and cell-free DNA from blood samples.

Point-of-care liquid biopsy platform for rapid cancer detection with 99% accuracy and high sensitivity. Delivers non-invasive screening results in minutes, enabling early diagnosis across multiple cancer types at a lower cost than conventional test kits.

Non-invasive liquid biopsy test for early-stage prostate cancer detection using glycan analysis in blood serum. Achieves up to 90% accuracy using magnetic particle-based technology with minimal blood sample requirement of 10 microliters.

A blood exosome detection kit for screening pancreatic cancer and cholangiocarcinoma. This diagnostic kit applies magneto-electrochemical detection technology and protein biomarker analysis for cancer identification.

Integrated platform for cancer diagnosis utilizing liquid biopsy techniques with CRISPR/Cas9 technology. Includes complete workflow from sample collection through DNA sequencing to result analysis.

Advanced early detection test for lung cancer screening utilizing molecular diagnostic technology. This in-development product represents the company's expansion into early detection for pulmonary malignancies. The test is designed for high-risk population screening and clinical intervention.

Molecular diagnostic test utilizing circulating tumor DNA and biomarkers from blood samples. Enables non-invasive cancer screening and early detection. Supports monitoring of treatment response and recurrence in cancer patients.